专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明公开

EP1876244A1 METHOD OF RELATIVE RISK FOR THE ONSET OF ATOPIC DERMATITIS BY GENE SINGLE NUCLEOTIDE POLYMORPHISM ANALYSIS 审中-公开
标题翻译： VERFAHREN ZUM RELATIVEN RISIKO DES AUSBRUCHS ATOPISCHER DERMATITIS MIT EINZELNUKLEOTIDPOLYMORPHISMUS-GENANALYSE
公开(公告)号：EP1876244A1
公开(公告)日：2008-01-09
申请号：EP06731010.2
申请日：2006-04-03
申请人： Asubio Pharma Co., Ltd.
发明人： TANAKA, Keiko, c/o University of Wales Swansea , HOPKIN, Julian M., c/o University of Wales Swansea
IPC分类号： C12Q1/68 , C12N15/09 , G01N33/53 , G01N37/00
CPC分类号： C12Q1/6883 , C12Q2600/156
摘要： The present invention provides a method of discriminating a relative risk for the morbidity of atopic dermatitis of a test subject comprising: analyzing gene polymorphism of two or more of genes related to onset of atopic dermatitis using a sample isolated from a statistically significant number of normal persons and patients of atopic dermatitis to determine relative ratios (percentages (%)) related to the individual gene polymorphism of individual derived from the analysis; and calculating an odds ratio according to specified gene polymorphism from the relative ratio; and using, as a discrimination criterion, a combination of two or more of gene polymorphisms showing a synergetically higher odds ratio than odds ratios according to individual gene polymorphism. The method is useful for predicting susceptibility of an AD patient to chemicals based on genes and for selecting the diagnostic and/or therapeutic agent by eliminating harmful drug reactions from the analysis of principal factors related to onset and development of AD and interaction among these genes, and for determining a diagnostic method and therapeutic method using the detection method of morbidity risk.
摘要翻译：本发明提供了一种鉴别测试对象的特应性皮炎发病率的相对危险度的方法，包括：使用从统计学上显着数量的正常人分离的样品分析与特应性皮炎发作相关的两个或多个基因的基因多态性和特应性皮炎患者确定与分析得出的个体个体基因多态性相关的相对比例（百分比（％））; 并根据相对比例根据规定的基因多态性计算优势比; 并且根据个体基因多态性，使用两种或更多种基因多态性的组合，其显示出比优势比的协同优势比值比。该方法可用于预测基于基因的AD患者对化学物质的敏感性，并且通过从与AD发生和发展以及这些基因之间的相互作用相关的主要因素的分析中消除有害药物反应来选择诊断和/或治疗剂，并用于确定使用发病风险检测方法的诊断方法和治疗方法。

42. 发明公开

EP1849793A1 PROCESS FOR PRODUCING CARBON-DIMINISHED ALDOSE COMPOUND 审中-公开
标题翻译： VERFAHREN ZUR HERSTELLUNG EINER ALDOSEVERBINDUNG MIT REDUZIERTER KOHLENSTOFFANZAHL
公开(公告)号：EP1849793A1
公开(公告)日：2007-10-31
申请号：EP05844822.6
申请日：2005-12-28
申请人： Asubio Pharma Co., Ltd.
发明人： OKITSU, Mitsuhito, Asubio Pharma Co., Ltd. , KAMEI, Katsuhide, Asubio Pharma Co., Ltd.
IPC分类号： C07H3/02 , C07H3/08 , C07C317/18 , C07C323/12
CPC分类号： C07C319/14 , C07C315/02 , C07H3/02 , C07H3/08 , C07C317/18 , C07C323/12
摘要： The present invention provides a process capable of industrially producing 5-deoxy-L-arabinose, important as a raw material for the production of sapropterin useful as a therapeutic agent for atypical hyperphenylalaninemia, satisfactorily efficiently even with a simple production apparatus. Provided is the process for producing 5-deoxy-L-arabinose characterized by including: reacting L-rhamnose with a C 11-16 straight chain alkyl mercaptan compound in the presence of an acid catalyst to prepare L-rhamnose dialkylmercaptal; subjecting then the obtained compound to an oxidation reaction to prepare a sulfonyl derivative; and subjecting then the sulfonyl derivative to a carbon-reduction reaction to prepare 5-deoxy-L-arabinose. The present production process can also be applied to a process for producing compounds obtained by removing one carbon atom from other aldol compounds, and thus the present invention provides a general process for producing compounds obtained by reducing the number of carbon atoms from aldose compounds.
摘要翻译：本发明提供一种能够工业生产5-脱氧-L-阿拉伯糖的方法，其作为生产用于非典型高苯丙氨酸血症的治疗剂的沙棘素的原料是重要的，即使使用简单的生产设备也能令人满意地有效地生产。本发明提供5-脱氧-L-阿拉伯糖的制备方法，其特征在于包括：在酸催化剂存在下使L-鼠李糖与C 11-16直链烷基硫醇化合物反应以制备L-鼠李糖二烷基酯; 然后将所得化合物进行氧化反应以制备磺酰基衍生物; 然后使磺酰基衍生物进行碳还原反应以制备5-脱氧-L-阿拉伯糖。本制备方法也可以应用于通过从其它醛醇化合物中除去一个碳原子获得的化合物的制备方法，因此本发明提供了通过从醛糖化合物中还原碳原子数得到的化合物的制备方法。

43. 发明授权

EP1454897B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY 无效转让
标题翻译： WITH PDE7锁定效果吡唑并嘧啶衍生物
公开(公告)号：EP1454897B1
公开(公告)日：2007-10-10
申请号：EP02788833.8
申请日：2002-12-13
申请人： Asubio Pharma Co., Ltd.
发明人： INOUE, Hidekazu , MURAFUJI, Hidenobu , HAYASHI, Yasuhiro
IPC分类号： C07D487/04 , A61K31/519 , A61P1/04
CPC分类号： C07D487/04
摘要： Pyrazolopyrimidinone derivatives represented by the general formula (IA) or (IB): (IA) (IB) or the general formula (IA’) or (IB’): (IA’) (IB’) (wherein each symbol is as defined in the description). The compounds can enhance the intracellular cAMP level by virtue of their selective inhibitory activity against PDE7, and are useful in the prevention and treatment of various allergic diseases and inflammatory and immunologic diseases through their inhibiting the activation of T cells.

44. 发明授权

EP1228367B1 AMINOPHENOXYACETAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF 有权
标题翻译： AMINOPHENOXYACETAMID衍生物和含有药物组合物
公开(公告)号：EP1228367B1
公开(公告)日：2007-09-26
申请号：EP01921835.3
申请日：2001-04-13
申请人： Asubio Pharma Co., Ltd.
发明人： TAKEMOTO, Naohiro , ANNOURA, Hirokazu , MURAYAMA, Norihito
IPC分类号： G01N33/15 , C07D211/58 , C07D417/04 , A61K31/4468 , A61P25/00 , G01N33/68
CPC分类号： C07D417/04 , C07D211/58
摘要： There is provided an aminophenoxyacetamide derivative of the formula (I): wherein, R1 to R4 are, independent from each other, hydrogen atom; optionally substituted alkyl group; E?1 is -NR4- and E2¿ is oxygen atom or -NR10; Q is group -X-Y-Q' (X and Y are connecting bond; X is alkylene or alkenylene group, etc.; Y is selected from the groups consisting of C=O, NHC(=O), C(=O)NH, etc.; Q' is hydrogen atom or pheny, pyridyl groups which may be substituted, etc.),or a pharmaceutically acceptable salt thereof.These compounds have neuroprotective effect by introducing the CalbindinD-28k, one of Ca2+-binding proteins.11

45. 发明公开

EP1820798A1 7-MEMBERED RING COMPOUND, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF 有权
标题翻译： 7元环，方法其制备方法及其医药用途CONNECTION
公开(公告)号：EP1820798A1
公开(公告)日：2007-08-22
申请号：EP05814413.0
申请日：2005-12-01
申请人： Asubio Pharma Co., Ltd.
发明人： MUTO, Tsuyoshi , TANAKA, Taisaku , MARUOKA, Hiroshi , IMAJO, Seiichi , TOMIMORI, Yoshiaki
IPC分类号： C07D243/08
CPC分类号： C07D243/08 , C07C233/47 , C07C271/22 , C07D213/79 , C07D213/80 , C07D243/10 , C07D307/68 , C07D333/40 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/06 , C07D405/12 , C07D409/12 , C07D413/12
摘要： A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved:

a method for producing the same, and a pharmaceutical composition useful for the prevention or treatment of diseases, in which chymase is involved, including the compound of having the formula (I), or its pharmaceutically acceptable salt, or a solvate thereof are provided.
摘要翻译：具有用于预防或治疗各种疾病，其中糜酶是所涉及的式（I）或其盐，或与糜酶抑制作用它们的溶剂合物和有用的7-元杂环化合物：其制造方法，和用于在其中的胃促胰酶的疾病的预防或治疗中有用的药物组合物参与其中，包括具有式（I）或其药学上可接受的盐，或溶剂化物被设置物的化合物。

46. 发明授权

EP1142586B1 USE OF CHYMASE INHIBITORS AGAINST VASCULAR LIPID DEPOSITION 有权
标题翻译：抑制剂的抗血管糜脂质沉积USE
公开(公告)号：EP1142586B1
公开(公告)日：2007-04-25
申请号：EP00971729.9
申请日：2000-11-01
申请人： Daiichi Asubio Pharma Co., Ltd.
发明人： FUKAMI, Harukazu , URATA, Hidenori
IPC分类号： A61K31/517 , A61P9/10
CPC分类号： A61K31/517 , C07D239/96
摘要： Preventive or therapeutic agents for diseases accompanied with vascular function disorders related to deposition of lipid on vessel walls, containing specific chymase inhibitors as the active ingredient. Quinazoline derivatives of general formula (1) are usable as the specific chymase inhibitor. In said formula, A is an aromatic ring.

47. 发明授权

EP0908182B2 PREVENTIVES OR REMEDIES FOR DISEASES INDUCED BY HYPOFUNCTION OF NITRIC OXIDE SYNTHASE (NOS) 失效
标题翻译：造成的氮氧化氮合酶LACK（NOS）用于疾病的预防或治疗剂跳闸ARE
公开(公告)号：EP0908182B2
公开(公告)日：2007-03-28
申请号：EP97937845.2
申请日：1997-08-29
申请人： Daiichi Asubio Pharma Co., Ltd.
发明人： ISHIHARA, Takafumi , KANAYAMA, Yoshiharu , OKAMURA, Mikio , YOSHIKAWA, Junichi , SHINTAKU, Haruo
IPC分类号： A61K31/505 , A61P37/00 , A61P25/00 , A61P9/00 , A61P1/00
CPC分类号： A61K31/525 , A61K31/519 , C07D475/04
摘要： Remedies containing as the active ingredient compounds represented by general formula (I) or pharmaceutically acceptable salts thereof, whereby diseases induced by the hypofunction of NOS can be efficaciously prevented or ameliorated, wherein R?1 and R2¿ represent each hydrogen, or R?1 and R2¿ form together a single bond; and R3 represents -CH(OH)CH(OH)CH¿3?, CH(OCOCH3)CH(OCOCH3)CH3, -CH3, -CH2OH or phenyl when R?1 and R2¿ are hydrogen, or R3 represents -COCH(OH)CH¿3? when R?1 and R2¿ form together a single bond.

48. 发明公开

EP1734112A1 METHOD OF PROLIFERATING PLURIPOTENT STEM CELL 有权
标题翻译： VERFAHREN ZUR PROLIFEATION EINER PLURPOTENTEN STAMMZELLE
公开(公告)号：EP1734112A1
公开(公告)日：2006-12-20
申请号：EP05727500.0
申请日：2005-03-23
申请人： Daiichi Asubio Pharma Co., Ltd. , Fukuda, Keiichi , Akaike, Toshihiro
发明人： AKAIKE, Toshihiro , FUKUDA, Keiichi , NAGAOKA, Masato , KOSHIMIZU, Uichi;
IPC分类号： C12N5/06 , C12N5/08 , C07K14/47 , C12N15/09
CPC分类号： C12N5/0606 , C12N2533/50
摘要： A novel growth method is provided for pluripotent stem cells such as ES cells. The method of the invention is a pluripotent stem cell growing method and gene transfer method in which pluripotent stem cells are cultured under conditions that maintain their undifferentiated state and pluripotency, the method being characterized by using a liquid medium and a culturing vessel having immobilized or coated on a substrate solid phase surface a molecule which is adhesive to the pluripotent stem cells in a fixed concentration, to grow the pluripotent stem cells in a dispersed state while maintaining their undifferentiated state and pluripotency, without using feeder cells, or to transfer and express a gene therein.
摘要翻译：为多能干细胞如ES细胞提供了一种新的生长方法。本发明的方法是多能干细胞生长方法和基因转移方法，其中多能干细胞在保持其未分化状态和多能性的条件下培养，该方法的特征在于使用液体培养基和具有固定或涂覆的培养容器在底物固相表面上以固定浓度与多能干细胞粘合的分子，以分散状态生长多能干细胞，同时保持其未分化状态和多能性，而不使用饲养细胞，或转移和表达基因。

49. 发明公开

EP1437339A4 SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-KAPPA B INHIBITING ACTIVITY 审中-公开
标题翻译：与NF-KAPPA-B锁效应取代苯甲酸
公开(公告)号：EP1437339A4
公开(公告)日：2006-10-04
申请号：EP02765501
申请日：2002-09-11
申请人： DAIICHI ASUBIO PHARMA CO LTD
发明人： SUZUKI KENJI , NUNOKAWA YOICHI
IPC分类号： A61K31/167 , A61K31/192 , A61K31/235 , A61K31/4409 , A61K31/4418 , A61K31/4453 , A61K31/4545 , A61K31/5375 , A61K31/5377 , A61P1/00 , A61P1/16 , A61P3/10 , A61P9/10 , A61P19/02 , A61P29/00 , A61P31/12 , A61P31/18 , A61P33/06 , A61P35/02 , A61P37/02 , A61P43/00 , C07C65/24 , C07C66/00 , C07C69/94 , C07C235/84 , C07D213/55 , C07D213/56 , C07D295/192 , C07D295/18
CPC分类号： C07D295/192 , A61K31/167 , A61K31/192 , A61K31/235 , A61K31/4409 , A61K31/4418 , A61K31/4453 , A61K31/4545 , A61K31/5375 , A61K31/5377 , C07C65/24 , C07C66/00 , C07C69/94 , C07C235/84 , C07D213/55 , C07D213/56
摘要： A substituted benzoic acid derivative which is represented by the following formula (I) and has an NF-kappaB inhibiting action (in the formula, R 3 , R 4 and R 5 each independently represents a hydrogen atom, an alkyl group having 1 to 6 carbon(s) or an alkoxy group having 1 to 6 carbon(s); R 9 and R 10 each independently represents a hydrogen atom, an alkyl group having 1 to 6 carbon(s) or an acyl group having 2 to 11 carbons); R 2 represents an optionally-substituted aromatic hydrocarbon group or an optionally-substituted heterocyclic group; and X represents a carboxyl group which may be esterified or amidated)

50. 发明公开

EP1693451A1 METHOD OF GROWING MYOCARDIAL CELLS 有权
标题翻译： VERFAHREN ZUR ANZUCHT VON MYOKARDZELLEN
公开(公告)号：EP1693451A1
公开(公告)日：2006-08-23
申请号：EP04818986.4
申请日：2004-11-19
申请人： Daiichi Asubio Pharma Co., Ltd.
发明人： ADACHI, Mimi , NAKAYAMA, Keiichi , KITAJIMA, Shigetaka , TAKAGI, Hiromitsu
IPC分类号： C12N15/09 , C12N5/10 , A61K31/7088 , A61K35/34 , A61K35/76 , A61K48/00 , A61P9/00 , A61P9/04 , A61P9/10
CPC分类号： C12N5/0657 , A61K31/7088 , A61K35/12 , A61K48/00 , C07K14/4738 , C12N9/1205 , C12N2510/00
摘要： The proliferation of cardiomyocytes is induced by expressing cyclin and CDK in the cardiomyocytes, and by suppressing the function or action of a Cip/Kip family protein or inhibiting the production of a Cip/Kip family protein. Among the Cip/Kip family proteins, it is preferable to suppress the function of p27 Kip1 or inhibiting the production thereof. As a recombinant vector to be used therefor, there is provided a vector comprising: (1) a cyclin gene; (2) a cyclin-dependent kinase gene; and (3) one or a plurality selected from the group consisting of a gene encoding a factor that inhibits the function or action of a Cip/Kip family protein and a nucleic acid sequence that inhibits the production of Cip/Kip family protein.
摘要翻译：通过在心肌细胞中表达细胞周期蛋白和CDK，抑制Cip / Kip家族蛋白的功能或作用或抑制Cip / Kip家族蛋白的产生来诱导心肌细胞的增殖。在Cip / Kip族蛋白质中，优选抑制p27 Kip1的功能或抑制其生产。作为用于其的重组载体，提供了载体，其包含：（1）细胞周期蛋白基因; （2）细胞周期蛋白依赖性激酶基因; 和（3）选自由编码抑制Cip / Kip家族蛋白的功能或作用的因子的基因和抑制Cip / Kip家族蛋白的产生的核酸序列组成的组中的一种或多种。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式